$OCEA Cashflow Statement | Understand Stock

$OCEA

$0.00 +$0.00 (0.0%) Close

$OCEA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 6 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Interest income from Trust Account
Non-cash interest expense
Non-cash debt issuance costs
Non-cash stock issuances
Stock-based compensation
Loss on issuance of warrants
Loss on extinguishment of debt
Loss on exchange of notes
Loss in connection with Share Consideration shares
Loss in connection with Backstop Put Option Liability and Fixed Maturity Consideration
Net loss attributable to equity interest in Virion
Change in fair value of Virion Contribution Liability
Change in fair value of 2023 Convertible Note, SPA Warrant and the Ayrton Note Purchase Option
Non-cash transaction costs in excess of Business Combination proceeds
Changes in assets and liabilities:
Prepaid expenses
Accounts Payable
Accrued Expenses
Accounts payable and accrued expenses
Accrued expenses - related parties
Net cash used in operating activities
Investment of cash in trust account
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance initial public offering
Proceeds from private placement warrants
Proceeds from issuance of founder shares
Proceeds from Founder Shares
Proceeds from issuance of promissory note to related party
Payment of deferred offering costs
Payment of promissory note to related party
Payment to Backstop Parties for Backstop Agreement
Payment to Backstop Parties for Share Consideration
Issuance of common stock pursuant to the Backstop Agreement and Subscription Agreement
Proceeds from Backstop Agreement
Proceeds from reverse recapitalization
Proceeds from 2023 Convertible Note
Proceeds from 2024 Convertible Notes
Proceeds from short-term loans, net of issuance costs
Proceeds from Common Stock Purchase Agreement
Repayments of short-term loans
Expenses paid by related-party shareholder
Net cash provided by financing activities

Total change in cash and restricted cash
Cash and restricted cash at beginning of period
Cash and restricted cash at end of period
Deferred underwriting commissions payable charged to additional paid-in-capital
Extension Funds attributable to common stock subject to redemption under ASC 480-10-S99 against APIC
Subsequent measurement of common stock subject to redemption
Supplemental disclosure of non-cash financing activities:
Offering costs not yet paid
Non-cash stock issuances
Non-cash investment in Virion
SPA warrant liability upon issuance
Warrants issued related to short term loans
Short term loans issuance costs not yet paid

Comments